2020 Fiscal Year Final Research Report
Development of antibody drugs for dogs against immune checkpoint molecules etc. with effector functions
Project/Area Number |
19K15969
|
Research Category |
Grant-in-Aid for Early-Career Scientists
|
Allocation Type | Multi-year Fund |
Review Section |
Basic Section 42020:Veterinary medical science-related
|
Research Institution | Hokkaido University |
Principal Investigator |
Maekawa Naoya 北海道大学, 獣医学研究院, 特任助教 (70829035)
|
Project Period (FY) |
2019-04-01 – 2021-03-31
|
Keywords | イヌ腫瘍 / 抗体医薬 / 免疫チェックポイント / がん免疫療法 |
Outline of Final Research Achievements |
In order to develop novel therapeutic agents for canine cancers, this study used genetic engineering techniques to produce antibody drug candidates for dogs with effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities. The antibodies were tested for antigen binding and effector activities, demonstrating expected biological activities in vitro, and no safety concerns were observed after repeated administration to dogs. We are now in the process of detailed analysis of the safety. This study has demonstrated the feasibility of producing antibody drugs for dogs with effector functions and has paved the way for their clinical application.
|
Free Research Field |
獣医学
|
Academic Significance and Societal Importance of the Research Achievements |
本研究で作製したADCC活性やCDC活性などのエフェクター機能を付与したイヌ用抗体は、イヌ難治性腫瘍に対する新しい治療の選択肢の一つとして臨床応用・実用化される可能性があり、小動物医療の高度化に貢献することが期待される。本研究はイヌに対する抗体医薬の創出のモデルケースとなり、後続研究へ応用されることで関連分野のさらなる発展が見込まれる。イヌ腫瘍に対する新規治療薬の開発は、ヒトの類似疾患に対する治療法の開発においても有効性や安全性等の情報を提供できることから、医薬品開発にも有益である可能性がある。
|